Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
AstraZeneca Acquires Drugs From Almirall
by Ann M. Thayer
August 4, 2014
| A version of this story appeared in
Volume 92, Issue 31
AstraZeneca will pay up to $2.1 billion for the respiratory drug business of Spain’s Almirall. The deal includes both marketed products and development-stage candidates. AstraZeneca is paying $875 million up front and the rest as products hit development and sales milestones. It also will get a subsidiary focused on devices for delivering respiratory drugs. In 2013, Almirall had sales of $1.1 billion. It will now focus on dermatology drugs and other specialty pharmaceuticals.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X